



**NEW YORK CITY DEPARTMENT OF
HEALTH AND MENTAL HYGIENE**

Ashwin Vasani, MD, PhD
Commissioner

June 24, 2024

Dear Provider,

The US Food and Drug Administration (FDA) has [updated its preference](#) for the 2024-2025 formulation of COVID-19 vaccines. The FDA initially advised manufacturers that the 2024-2025 COVID-19 vaccines should target the JN.1 strain, but has since determined that the KP.2 strain is preferred, if feasible. A vaccine targeting the KP.2 strain will more closely match circulating SARS-CoV-2 strains. The FDA does not anticipate that a change to KP.2 will delay the availability of the vaccines in the US.

If you have any questions, please contact nycimmunize@health.nyc.gov.

Sincerely,

A handwritten signature in black ink that reads 'Bindy Crouch'.

Bindy Crouch, MD, MPH
Assistant Commissioner
Bureau of Immunization